Update on Gastroesophageal Adenocarcinoma Targeted Therapies

Publication date: June 2017
Source:Hematology/Oncology Clinics of North America, Volume 31, Issue 3
Author(s): Steven B. Maron, Daniel V.T. Catenacci

Teaser

Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is declining in the United States, proximal esophagogastric junction adenocarcinoma (EGJ) incidence is rising. GC and EGJ, together, are treated uniformly in the metastatic setting as GEC. Overall survival in the metastatic setting remains poor, with few molecular targeted approaches having been successfully incorporated into routine care to date—only first-line anti-HER2 therapy for ERBB2 amplification and second-line anti-VEGFR2 therapy. This article reviews aberrations in epidermal growth factor receptor, MET, and ERBB2, their therapeutic implications, and future directions in targeting these pathways.


http://ift.tt/2q6ZQeW